Guardant Health Raises FY24 Revenue From $690M-$700M To $720M-$725M Vs $695.221M Est.
GHNovember 6, 2024
Read more →Guardant Health Q3 2024 Adj. EPS $(0.45) Beats $(0.74) Estimate, Sales $191.500M Beat $170.625M Estimate
GHNovember 6, 2024
Read more →What's Going On With Colorectal Cancer Diagnostic-Focused Guardant Health Stock On Tuesday?
GHFDA staff reviewers raise concerns over Guardant Health's experimental Shield blood test for colorectal cancer, citing low sensitivity in detecting certain tumor types. Shield aims to improve early CRC detection and compliance, potentially extending patient survival.
May 21, 2024
Read more →Guardant Health Receives EU IVDR Certification For Its Guardant360 CDx Blood Test
GHMay 21, 2024
Read more →Guardant Health's Real-World Data Supporting Performance Of Shield Blood Test For CRC Presented At 2024 Digestive Disease Week
GHMay 16, 2024
Read more →Guardant Health Announces Shield Blood Test Available In U.S. To Detect Early Signs Of Colorectal Cancer In Average-Risk Adults
GHMay 2, 2022
Read more →